Rev Med UAS
Vol. 12: No. 4. Octubre-Diciembre 2022
ISSN 2007-8013

Incidencia de enfermedad por reflujo gastroesofágico posterior a erradicación de helicobacter pylori en México. Estudio-cuasiexperimental

Incidence of gastroesophageal reflux disease after helicobacter pylori eradication in Mexico. Quasi-experimental study

Jaime Alberto Sánchez-Cuén1,2*, Fernando Rosas López-Portillo2, Jesús Gámez-Valenzuela2, Gregorio Bernal-Magaña1, Jesús Roberto Garay-Núñez3, Ana Bertha Irineo-Cabrales1

  1. Hospital Regional ISSSTE Culiacán, Servicio de Gastroenterología del Hospital Regional ISSSTE Culiacán, Sinaloa, México.
  2. Facultad de Medicina, Universidad Autónoma de Sinaloa, México.
  3. Escuela Superior de Enfermería, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa México.

* Correspondencia: Jaime Alberto Sánchez-Cuén.
Departamento de Gastroenterología. Hospital Regional ISSSTE de Culiacán.
Calzada Heroico Colegio Militar, 875 sur, colonia 5 de Mayo. 80000 Culiacán, Sinaloa. México
e-mail: sanchezcuen_jaime@hotmail.com

DOI http://dx.doi.org/10.28960/revmeduas.2007-8013.v12.n4.002

Texto Completo PDF

Recibido 22 de septiembre 2022, aceptado 26 de octubre 2022

RESUMEN
Objetivo. Fue determinar la incidencia de Enfermedad por Reflujo Gastroesofágico posterior a la erradicación exitosa de la infección por Helicobacter pylori en un hospital de especialidades. --- Material y métodos. Se realizó un estudio cuasi-experimental, en pacientes sin antecedentes de reflujo gastroesofágico con infección por Helicobacter pylori que recibieron terapia triple estándar exitosa. Se dio seguimiento para identificar síntomas de reflujo y endoscopia digestiva a un año posterior. Estadística con prueba exacta de Fisher y McNemar. --- Resultados. Fueron estudiados 58 pacientes, la edad media fue 57,1 (DE 13,2) años, siendo 37 (63,8%) mujeres y 21 (36,2%) hombres. La indicación endoscópica más frecuente fue la dispepsia en 38 (65,5%) pacientes. La incidencia de enfermedad por reflujo fue en 20 (34,5%) pacientes al año de seguimiento. La enfermedad por reflujo erosiva y no erosiva fue en 10 (17,2%) pacientes en ambas. --- Conclusiones. La incidencia de enfermedad por reflujo posterior a la erradicación de Helicobacter pylori con terapia triple estándar es alta al igual que en otros países del mundo.
Palabras clave: Incidencia, Helicobacter pylori, Reflujo Gastroesofágico.

ABSTRACT
Objective. It was to determine the incidence of Gastroesophageal Reflux Disease after the successful eradication of Helicobacter pylori infection in a specialty hospital. --- Materials and methods. A quasi-experimental study was carried out. The population studied were subjects with no history of gastroesophageal reflux, an upper gastrointestinal endoscopy was performed, confirming Helicobacter pylori infection, and they received successful standard triple therapy. Consultation follow-up to identify symptoms of gastroesophageal reflux and upper gastrointestinal endoscopy one year later. Statistical design with Fisher and McNemar exact test. --- Results. We reviewed 58 subjects, 37 (63, 8%) women and 21 (36, 2%) men. mean age was 57, 1 years (SD 13, 2). The most fre-quent indication for endoscopy was dyspepsia in 38 (65, 5%) subjects. The incidence of reflux disease was in 20 (34, 5%) subjects at one year of follow-up. Erosive and non-erosive reflux disease was in 10 (17, 2%) subjects in both. Conclusions. The incidence of reflux disease after Helicobacter pylori eradication with standard triple therapy as high as other countries in the world.
Key words: Incidence, Helicobacter pylori, Gastroesophageal reflux.

REFERENCIAS

  1. Scida S, Russo M, Miraglia C, Leandro G, Franzoni L, Meschi T, et al. Relationship between Helicobacter pylori infection and GERD. Acta Biomed 2018; 17; 89(8-S):40-43.
  2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence based consensus. Am J Gastroenterol 2006; 101: 1900-20.
  3. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-esophageal reflux disease: a systematic review. Gut 2014; 63(6):871-80.
  4. Sukano K. Vonoprazan fumarate, a novel potassium –competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 2018 9; 11:1756283X17745776.
  5. Herrera EJL, Monreal RR, García CD, González MEI, Borjas AOD, Maldonado GHJ, et al. Prevalence of Barrett's esophagus: An observational study from a gastroenterology clinic. Rev Gastroenterol Mex 2017; 82(4):296-300.
  6. Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJPM, et al. Modern diagnosis of GERD: the Lyon Consensus Gut 2018; 67(7):1351-1362.
  7. Gislason T, Janson C, Vermeire P, Plaschke P, Björnsson E, Gislason D ,et al. Respiratory symptoms and nocturnal gastro-esophageal reflux: A population based study of young adults in three European countries. Chest 2002; 121:158-63.
  8. Akyüz F, Mutluay Soyer Ö. Which diseases are risk factors for developing gastroesophageal reflux disease? Turk J Gastroenterol 2017; 28(Suppl 1):S44-S47.
  9. Akyüz F, Mutluay Ö. How is gastroesophageal reflux disease classified? Turk J Gastroenterol 2017; 28 (Suppl 1): S10-S11.
  10. Vaishnav B, Bamanikar A, Maske P, Reddy A, Dasgupta S. Gastroesophageal Reflux Disease and its Association with Body Mass Index: Clinical and Endoscopic Study. J Clin Diagn Res 2017; 11(4):OC01-OC04.
  11. Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterol 2018; 154(2): 267–276.
  12. Huerta F. Enfermedad por reflujo no erosiva. Rev Gastroenterol Mex 2006; 71(Supl. 1): 60-61.
  13. Gasiorowska A. The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease. Prz Gastroenterol 2017; 12(4):244-249.
  14. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol 2014; 20(18):5191-204.
  15. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterol 2017; 153(2):420-429.
  16. Alarid-Escudero F, Enns EA, MacLehose RF, Parsonnet J, Torres J, Kuntz KM. Force of infection of Helicobacter pylori in Mexico: evidence from a national survey using a hierarchical Bayesian model. Epidemiol Infect 2018; 146(8):961-969.
  17. Bae SE, Choi KD, Choe J. The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations. Helicobacter 2018.
  18. Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut 2018 1; 67 2092-6. (12).
  19. Yucel O. Interactions between Helicobacter pylori and gastroesophageal reflux disease. Esophagus 2019 ;16(1):52-62.
  20. Mungan Z, Pınarbaşı Şimşek B. Gastroesophageal reflux disease and the relationship with Helicobacter pylori. Turk J Gastroenterol 2017; 28 (Suppl 1): S61-S67.
  21. Ghoshal UC, Chourasia D. Gastroesophageal Reflux Disease and Helicobacter pylori: What May Be the Relationship?. J Neurogastroenterol Motil 2010; 16(3):243-50.
  22. Jie W, Qinghong X, Zhitao Ch. Association of Helicobacter pylori infection with gastroesophageal reflux disease. J Int Med Res 2019; 47(2): 748–753.
  23. Nakajima S, Hattori T. Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy. Helicobacter 2003; 8(4):279-93.
  24. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis 2012;13:2-9.
  25. Peetsalu A, Kirsimägi U, Peetsalu M. Giant peptic ulcer hemorrhages: Epidemiology, treatment, and outcome in the teaching hospital of Tartu. Medicina (Kaunas) 2011; 47(1):19-24.
  26. Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95(4):914-20.
  27. Abdo-Francis JM, Uscanga-Domínguez LF, Sobrino-Cossio S, Rivera- Ramos JF, Huerta-Higa F, Tamayo de la Cuesta JL, et al. Tercer consenso mexicano de Helicobacter pylori. Rev Gastroenterol Mex 2007; 72(3):321-38.
  28. Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14(6):729-35.
  29. Inoue H, Imoto I, Taguchi Y, Kuroda M, Nakamura M, Horiki N, et al. Reflux esophagitis after eradication of Helicobacter pylori is associated with the degree of hiatal hernia. Scand J Gastroenterol 2004; 39(11):1061-5.
  30. Pasechnikov VD, Chotchaeva AR, Pasechnikov DV. [Effect of HP eradication on the development of gastroesophageal reflux disease: results of the prospective study]. Eksp Klin Gastroenterol 2011 ;( 3):105-10.